Abstract: TH-PO805
Incidence and Association of Urologic Malignancies with ESRD: A Meta-Analysis
Session Information
- Dialysis: Epidemiology, Outcomes, Clinical Trials - Non-Cardiovascular - I
November 02, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Dialysis
- 607 Dialysis: Epidemiology, Outcomes, Clinical Trials - Non-Cardiovascular
Authors
- Kompotiatis, Panagiotis, Mayo Clinic, Rochester, Minnesota, United States
- Thongprayoon, Charat, Bassett Medical Center, Cooperstown, New York, United States
- Manohar, Sandhya, Mayo Clinic, Rochester, Minnesota, United States
- Cheungpasitporn, Wisit, Mayo Clinic, Rochester, Minnesota, United States
- Herrmann, Sandra, Mayo Clinic, Rochester, Minnesota, United States
Background
Previous studies have suggested higher incidence of urologic malignancies in patients with end-stage renal disease (ESRD). However, incidence trends of urologic malignancies in ESRD patients remain unclear. The study’s aims were 1) to investigate the pooled incidence/incidence trends 2) to assess the risks of urologic malignancies in ESRD patients.
Methods
A literature search was performed using MEDLINE, EMBASE and Cochrane Database from inception through April 2017. Studies that reported incidence or odd ratios (OR) of urologic malignancies among ESRD patients were included. Pooled OR and 95%CI were calculated using a random-effect model. The protocol for this study is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42017067687).
Results
Eighteen observational studies with 1,872,952 ESRD patients were included. The pooled estimated incidence of kidney cancer and bladder cancer in ESRD patients were 0.4% (95%CI: 0.3%-0.6%) and 0.5% (95%CI: 0.3%-0.7%), respectively. Meta-regression showed significant positive correlation between incidence of urologic malignancies in ESRD patients and year of study (slopes=+0.06, p<0.001 for both kidney and bladder cancers).
Compared to non-ESRD status, ESRD was significantly associated with both kidney cancer (pooled OR 5.68; 95% CI 4.39-7.35) and bladder cancer (pooled OR 3.82; 95% CI 2.51-5.82).
Conclusion
Our study demonstrates a significant association between ESRD and urologic malignancies. The overall estimated incidence rates of kidney cancer and bladder cancer are 0.4% and 0.5%, respectively. There is also a significant positive correlation between the incidence of urologic malignancies and year of study.